Evidence map›Paper›PMID 26969081›Full record

ArticleHaematologica2016

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Bipin N Savani, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Gerhard Ehninger, Dietger Niederwieser, Rainer Schwerdtfeger, Donald Bunjes, Bertram Glass, Gerard Socié and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Bipin N SavaniVanderbilt University Medical Center, Nashville, TN, USA Acute Leukemia Working Party, EBMT Paris study office / CEREST-TC, France bipin.savani@vanderbilt.edu.
Myriam LabopinAcute Leukemia Working Party, EBMT Paris study office / CEREST-TC, France Department of Haematology, Saint Antoine Hospital, Paris, France INSERM UMR 938, Paris, France Université Pierre et Marie Curie, Paris, France.
Nicolaus KrögerUniversity Hospital Eppendorf, Department of Stem cell Transplantation, Hamburg, Germany.
Jürgen FinkeUniversity of Freiburg, Department of Medicine -Hematology, Oncology, Germany.
Gerhard EhningerUniversitaetsklinikum Dresden, MedizinischeKlinik und Poliklinik I, Germany.
Dietger NiederwieserUniversity Hospital Leipzig, Div. Hematology, Oncology and Hemostasiology, Germany.
Rainer SchwerdtfegerHelios-Klinikum Berlin-Buch, Dept. Hematology Berlin, Germany.
Donald BunjesKlinik fuer Innere Medzin III - Universitätsklinikum Ulm, Germany.
Bertram GlassAsklepios Klinik St. Georg - Department of Haematology, Hamburg, Germany.
Gerard SociéHopital St. Louis - Dept.of Hematology, Paris, France.
Per LjungmanKarolinska University Hospital, Department of Hematology, Stockholm, Sweden.
Charles CraddockCenter for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, UK.
Frédéric BaronDepartment of Medicine, Division of Hematology, University of Liège, Belgium.
Fabio CiceriDepartment of Hematology, Ospedale San Raffaele, Università degli Studi, Milan, Italy.
Norbert Claude GorinFaculté de Médicine Saint-Antoine, Paris, France.
Jordi EsteveDept. of Hematology, Hospital Clinic, Barcelona, Spain.
Christoph SchmidKlinikum Augsburg, Dept. of Hematology and Oncology, University of Munich, Augsburg, Germany.
Sebastian GiebelMaria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.
Mohamad MohtyAcute Leukemia Working Party, EBMT Paris study office / CEREST-TC, France Department of Haematology, Saint Antoine Hospital, Paris, France INSERM UMR 938, Paris, France Université Pierre et Marie Curie, Paris, France.
Arnon NaglerAcute Leukemia Working Party, EBMT Paris study office / CEREST-TC, France Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome of patients undergoing HLA-matched unrelated donor allogeneic hematopoietic cell transplantation following reduced-intensity conditioning or myeloablative regimens is reported to be equivalent; however, it is not known if the intensity of the conditioning impacts outcomes after mismatched unrelated donor transplantation for acute myeloid leukemia. Eight hundred and eighty three patients receiving reduced-intensity conditioning were compared with 1041 myeloablative conditioning regimen recipients in the setting of mismatched unrelated donor transplantation. The donor graft was HLA-matched at 9/10 in 872 (83.8%) and at 8/10 in 169 (16.2%) myeloablative conditioning recipients, while in the reduced-intensity conditioning cohort, 754 (85.4%) and 129 (14.6%) were matched at 9/10 and 8/10 loci, respectively. Myeloablative conditioning regimen recipients were younger, 70% being <50 years of age compared to only 30% in the reduced-intensity conditioning group (P=0.0001). Significantly, more patients had secondary acute myeloid leukemia (P=0.04) and Karnofsky Performance Status score <90% (P=0.02) in the reduced-intensity conditioning group. Patients <50 and ≥50 years were analyzed separately. On multivariate analysis and after adjusting for differences between the two groups, reduced-intensity conditioning in patients age ≥50 years was associated with higher overall survival (HR 0.78; P=0.01), leukemia-free survival (HR 0.82; P=0.05), and decreased non-relapse mortality (HR 0.73; P=0.03). Relapse incidence (HR 0.91; P=0.51) and chronic graft-versus-host disease (HR 1.31; P=0.11) were, however, not significantly different. In patients <50 years old, there were no statistically significant differences in overall survival, leukemia-free survival, relapse incidence, non-relapse mortality, and chronic graft-versus-host-disease between the groups. Our study shows no significant outcome differences in patients younger than 50 years receiving reduced-intensity vs myeloablative conditioning regimens after mismatched unrelated donor transplantation. Furthermore, the data support the superiority of reduced-intensity conditioning regimens in older adults receiving transplants from mismatched unrelated donors.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningUnrelated DonorsAdultAgedAged, 80 and overAge FactorsFemaleGraft SurvivalGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedRecurrenceRetrospective Studies

Identifiers

PMID26969081
PMCPMC5013965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.